Kypha, Inc.

Kypha is an early-stage company developing new products to improve the way inflammation and immune activity is monitored and treated.

Micro_logo
St. Louis, MO, USA
Biotechnology

Company Overview

Kypha is currently advancing its lead product, the CompAct™ Test, toward FDA clearance and market launch in 2013. The test uses advanced detection technology and a robust point-of-care format to allow early, accurate detection and real-time monitoring of autoimmune and severe inflammatory disorders. For these patients and their physicians, careful monitoring and early detection are critical to managing disease activity and improving outcomes.

Management Team

  • Default_avatar

    Chad Michael Stiening

    CEO
    Unconfirmed
    Dr. Stiening is a business development executive with a PhD in life sciences and career focus on technology commercialization. He has studied and worked in the life sciences arena for over 15 years, including academic, large industry and start-up experience. His passion for the "business of science" was realized during his first internship with Monsanto, and evidenced by dual degrees in biology and finance.
  • Default_avatar

    Paul Kenneth Olson

    President and CSO
    Unconfirmed
    Dr. Olson was co-founder and CSO of Potentia Pharmaceuticals, which developed the world's first complement inhibitor to treat age-related macular degeneration. The drug was acquired in late 2009 by Alcon and is currently in Phase II clinicals. Prior to his start-up experiences, he held research positions at Harvard and Merck. He's worked closely with several world-renowned thought leaders in immunology, gene delivery and ophthalmology.

Company Info

Prototype Ready
5 Employees
Founded: September 2009

Advisors

  • Default_avatar

    Andrew Hoyne (Polsinelli Shughart)

    Lawyer
    Unconfirmed
  • Default_avatar

    Marie Carlie, Linda West (Stone Carlie)

    Accountant
    Unconfirmed

Previous Investors

  • Default_avatar

    BioGenerator

    Unconfirmed
  • Default_avatar

    Invidiual angel investors (US only)

    Unconfirmed